While Larotrectinib sulfate had only prohibited NTRK2 and NTRK3, Prasugrel—a thienopyridine adenosine diphosphate (ADP) receptor antagonist for the reduction of acute myocardial infarction in individuals with acute coronary syndrome after percutaneous coronary intervention (PCI) (Metkus et al. 2024)—could only present inhibitory effects against NTRK1. This evidence concerns the gene NTRK3 and acute coronary syndrome.